Search - tctmd.com

Displaying 481 - 500 of 868

Sort: Relevancy | Date

Presentation TCT 2015

A Randomized Comparison Among Drug Eluting Balloon, Drug Eluting Stents, and Conventional Balloon Angioplasty for Lesions in the Distal Internal Pudendal Artery in Patients with Erectile Dysfunction: The Perfect-3 Study

Presenter: Andrea Abizaid, Daniel Burkhoff, Tzung-Dau Wang

October 14, 2015

Presentation TCT 2015

PANDA III: A Prospective Randomized Trial of 2 Sirolimus-Eluting Bioresorbable-Polymer–Based Metallic Stents With Varying Elution and Absorption Kinetics

Presenter: Bo Xu

October 14, 2015

Presentation TCT 2015

TUXEDO: A Prospective Randomized Trial of Paclitaxel-Eluting vs Everolimus-Eluting Stents in Diabetic Patients With Coronary Artery Disease

Presenter: Upendra Kaul

October 14, 2015

News Conference News TCT 2015

TWENTE: ZES, EES Convey Similar Safety, Efficacy Results at 5 Years

October 14, 2015

News Conference News TCT 2015

TUXEDO-India Affirms Superiority of EES in Patients With Diabetes

Todd Neale

October 14, 2015

News Conference News TCT 2015

TCT Remembers Liliana Grinfeld, MD, PhD

October 14, 2015

News Conference News TCT 2015

PANDA III: BuMA SES Noninferior to Excel SES for TLF at 1 Year

October 14, 2015

News Conference News TCT 2015

MASTER: Positive Results Seen for Bioresorbable-Polymer DES in STEMI

October 14, 2015

News Conference News TCT 2015

ISAR-DESIRE 4: Scoring Balloon Predilation Effective at 1 Year in Patients With DES Restenosis

October 14, 2015

Presentation TCT 2015

TCT 66: Long-term Clinical Outcomes of Percutaneous Coronary Intervention Using Drug-Eluting Stent for Native Coronary Chronic Total Occlusion

Presenter: Sigmund Silber, Philip M. Urban, Pil Hyung Lee

October 13, 2015

Presentation TCT 2015

TCT 65: Two-Year Outcomes in Real-World Patients Treated With a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent in the PROMUS Element Plus US Postapproval Study (PE-Plus PAS)

Presenter: Sigmund Silber, Philip M. Urban, David E. Kandzari

October 13, 2015

Presentation TCT 2015

TCT 64: Incidence, Predictors, and Impact of Postdischarge Bleeding Compared to Myocardial Infarction After Percutaneous Coronary Intervention

Presenter: Sigmund Silber, Philip M. Urban, Philippe Généreux

October 13, 2015

Presentation TCT 2015

TCT 6: Five-Year Optical Coherence Tomography of Patients With ST-Elevation Myocardial Infarction Treated With Bare-Metal Versus Everolimus-Eluting Stents (the RE-EXAMINATION Study)

Presenter: Eric Boersma, Richard Smalling, Josep Gomez Lara

October 13, 2015

Presentation TCT 2015

TCT 15: Multislice Computed Tomography Assessment of Absorb Bioresorbable Vascular Scaffold in Comparison With Metallic Drug-Eluting Stents Data From the ABSORB Japan Trial

Presenter: Stephen G. Ellis, Lorenz Raber, Kengo Tanabe

October 13, 2015

Presentation TCT 2015

TCT 63: One-Year Results of the REMEDEE Registry Clinical Outcomes After Deployment of the Abluminal Sirolimus-Coated Bioengineered Stent in a Multicenter, Prospective Postmarket Registry

Presenter: Sigmund Silber, Philip M. Urban, Robert de Winter

October 13, 2015

Presentation TCT 2015

TCT 47: Comparative Optical Coherent Tomographic Analysis of In-Stent Neoatherosclerosis Between First- and Second-Generation Drug-Eluting Stents

Presenter: Stephan Achenbach, Marc D. Feldman, Mineok Chang

October 13, 2015

Presentation TCT 2015

TCT 62: Predicting Value of Platelet Reactivity on Bleeding and Major Adverse Cardiac Events in Eastern Asian Percutaneous Coronary Intervention Patients

Presenter: Sigmund Silber, Philip M. Urban, Wenyao Wang

October 13, 2015

Presentation TCT 2015

TCT 76: Six Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention With Biodegradable-Polymer Sirolimus-Eluting Stents for Bifurcation Lesions Insights From the I-LOVE-IT 2 Trial

Presenter: Lisa K. Jennings, Neal S. Kleiman, Bo Xu

October 13, 2015

Presentation TCT 2015

TCT 19: Two-Year Clinical Outcomes and Chest Pain in 1,811 All-Comer Patients, Treated for Bifurcated Versus Nonbifurcated Lesions With Highly Deliverable Drug-Eluting Coronary Stents

Presenter: Eric A. Cohen, Truls Råmunddal, Liefke van der Heijden

October 13, 2015

Presentation TCT 2015

TCT 60: Long Coronary Lesions Treated With a Bioresorbable-Polymer Drug-Eluting Stent Experience From eNOBORI Registry

Presenter: Sigmund Silber, Philip M. Urban, Evgeny Kretov

October 13, 2015

Advertisement

A Randomized Comparison Among Drug Eluting Balloon, Drug Eluting Stents, and Conventional Balloon Angioplasty for Lesions in the Distal Internal Pudendal Artery in Patients with Erectile Dysfunction: The Perfect-3 Study

PANDA III: A Prospective Randomized Trial of 2 Sirolimus-Eluting Bioresorbable-Polymer–Based Metallic Stents With Varying Elution and Absorption Kinetics

TUXEDO: A Prospective Randomized Trial of Paclitaxel-Eluting vs Everolimus-Eluting Stents in Diabetic Patients With Coronary Artery Disease

TWENTE: ZES, EES Convey Similar Safety, Efficacy Results at 5 Years

TUXEDO-India Affirms Superiority of EES in Patients With Diabetes

TCT Remembers Liliana Grinfeld, MD, PhD

PANDA III: BuMA SES Noninferior to Excel SES for TLF at 1 Year

MASTER: Positive Results Seen for Bioresorbable-Polymer DES in STEMI

ISAR-DESIRE 4: Scoring Balloon Predilation Effective at 1 Year in Patients With DES Restenosis

TCT 66: Long-term Clinical Outcomes of Percutaneous Coronary Intervention Using Drug-Eluting Stent for Native Coronary Chronic Total Occlusion

TCT 65: Two-Year Outcomes in Real-World Patients Treated With a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent in the PROMUS Element Plus US Postapproval Study (PE-Plus PAS)

TCT 64: Incidence, Predictors, and Impact of Postdischarge Bleeding Compared to Myocardial Infarction After Percutaneous Coronary Intervention

TCT 6: Five-Year Optical Coherence Tomography of Patients With ST-Elevation Myocardial Infarction Treated With Bare-Metal Versus Everolimus-Eluting Stents (the RE-EXAMINATION Study)

TCT 15: Multislice Computed Tomography Assessment of Absorb Bioresorbable Vascular Scaffold in Comparison With Metallic Drug-Eluting Stents Data From the ABSORB Japan Trial

TCT 63: One-Year Results of the REMEDEE Registry Clinical Outcomes After Deployment of the Abluminal Sirolimus-Coated Bioengineered Stent in a Multicenter, Prospective Postmarket Registry

TCT 47: Comparative Optical Coherent Tomographic Analysis of In-Stent Neoatherosclerosis Between First- and Second-Generation Drug-Eluting Stents

TCT 62: Predicting Value of Platelet Reactivity on Bleeding and Major Adverse Cardiac Events in Eastern Asian Percutaneous Coronary Intervention Patients

TCT 76: Six Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention With Biodegradable-Polymer Sirolimus-Eluting Stents for Bifurcation Lesions Insights From the I-LOVE-IT 2 Trial

TCT 19: Two-Year Clinical Outcomes and Chest Pain in 1,811 All-Comer Patients, Treated for Bifurcated Versus Nonbifurcated Lesions With Highly Deliverable Drug-Eluting Coronary Stents

TCT 60: Long Coronary Lesions Treated With a Bioresorbable-Polymer Drug-Eluting Stent Experience From eNOBORI Registry

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content